

09/26/01

09-27-01

A/Boeby

<p><b>UTILITY PATENT APPLICATION TRANSMITTAL</b>  <i>Submit an original and a duplicate for fee processing  (Only for new nonprovisional applications under 37 CFR §1.53(b))</i></p>		Attorney Docket No.	213257
		First Inventor	KOVESDI, Imre
		Title	COMPLEMENTARY ADENOVIRAL VECTOR SYSTEMS AND CELL LINES
		Express Mail No.	EJ905695499US
<p><b>APPLICATION ELEMENTS</b></p> <p>1. <input checked="" type="checkbox"/> Utility Patent Application Transmittal Form  2. <input type="checkbox"/> Applicant claims small entity status.  See 37 CFR 1.27.  3. <input checked="" type="checkbox"/> Specification (including claims and abstract)  [Total Pages 41]  4. <input checked="" type="checkbox"/> Drawings [Total Sheets 4]  <input checked="" type="checkbox"/> Combined Declaration and  Power of Attorney [Total Pages 4]  a. <input type="checkbox"/> Unexecuted  b. <input checked="" type="checkbox"/> Copy from prior application  [Note Box 6 below]  i. <input type="checkbox"/> <u>Deletion of Inventor(s)</u> Signed statement  attached deleting inventor(s) named in the prior  application  <input checked="" type="checkbox"/> Incorporation by Reference: The entire  disclosure of the prior application, from which  an oath or declaration is supplied under Box  5b is considered as part of the disclosure of  the accompanying application and is hereby  incorporated by reference.  <input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76  <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or  Computer Program (Appendix)  9. Nucleotide and/or Amino Acid Sequence  Submission  a. <input checked="" type="checkbox"/> Computer Readable Form (CRF)  b. Specification Sequence Listing on:  i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or  ii. <input checked="" type="checkbox"/> Paper Copy  c. <input checked="" type="checkbox"/> Statement verifying identity of above  copies</p>		ADDRESS TO:	Assistant Commissioner for Patents Box Patent Application Washington, DC 20231
<p><b>ACCOMPANYING APPLICATION PARTS</b></p> <p>10. <input type="checkbox"/> Applicant requests early publication. (include  publication fee under 37 CFR 1.18(d))  11. <input type="checkbox"/> Assignment Papers  (cover sheet and document(s))  12. <input type="checkbox"/> 37 CFR 3.73(b) Statement (when there is an  Assignee)  13. <input type="checkbox"/> Power of Attorney  14. <input type="checkbox"/> English Translation Document (if applicable)  15. <input type="checkbox"/> Information Disclosure Statement (IDS)  <input type="checkbox"/> Form PTO-1449  <input type="checkbox"/> Copies of Listed Documents  16. <input checked="" type="checkbox"/> Preliminary Amendment  17. <input checked="" type="checkbox"/> Return Receipt Postcard  (Should be specifically itemized)  18. <input type="checkbox"/> Certified Copy of Priority Document(s)  19. <input type="checkbox"/> Request &amp; Certification Under 35 USC  122(b)(2)(B)(i) (Form PTO/SB/35 or its equivalent attached)  20. <input checked="" type="checkbox"/> Other:  Request for Declaration of Interference.  Amendments to Specification Made by Preliminary  Amendment.  Amendments to Claims Made by Preliminary  Amendment.  Pending Claims After Preliminary Amendment.</p>			
<p>21. If a <b>CONTINUING APPLICATION</b>, check appropriate box and supply the requisite information in (a) and (b)  below:</p> <p>(a) <input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part of prior Application No. , filed on ,  Prior application information: Examiner ; Group Art Unit:</p> <p>(b) Preliminary Amendment: Benefit of earlier filing date - 35 USC 120. The Commissioner is requested to  amend the specification by inserting the following sentence before the first line:  "This is a <input checked="" type="checkbox"/> continuation <input type="checkbox"/> divisional <input type="checkbox"/> continuation-in-part (CIP) of  <input checked="" type="checkbox"/> Application No. 08/258,416, filed on June 10, 1994, which is incorporated by reference."  <input type="checkbox"/> International Application No. , filed on , which designates the U.S., and which is  incorporated by reference."</p>			

UTILITY PATENT APPLICATION TRANSMITTAL			Attorney Docket No.	213257
APPLICATION FEES				
BASIC FEE				\$ 710.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total Claims	13 - 20 =	0	x \$18.00	\$ 0.00
Independent Claims	3 - 3 =	0	x \$80.00	\$ 0.00
<input type="checkbox"/> Multiple Dependent Claim if applicable				+\$270.00
				\$ 0.00
				Total of above calculations =
				\$ 710.00
				Reduction by 50% for filing by small entity =
				(\$ 0.00)
<input type="checkbox"/> Assignment fee if applicable				+ \$40.00
<input type="checkbox"/> Early publication fee if applicable				+ \$300.00
				\$ 0.00
				TOTAL =
				\$ 710.00

22.  Please charge my Deposit Account No. 12-1216 in the amount of \$ 710.00.


23.  A check in the amount of \$ \_\_\_\_\_ is enclosed.

24. The Commissioner is hereby authorized to credit overpayments or charge any additional fees of the following types to Deposit Account No. 12-1216:

- Fees required under 37 CFR 1.16.
- Fees required under 37 CFR 1.17.

25.  The Commissioner is hereby generally authorized under 37 CFR 1.136(a)(3) to treat any future reply in this or any related application filed pursuant to 37 CFR 1.53 requiring an extension of time as incorporating a request therefor, and the Commissioner is hereby specifically authorized to charge Deposit Account No. 12-1216 for any fee that may be due in connection with such a request for an extension of time.

26. CORRESPONDENCE ADDRESS

<input checked="" type="checkbox"/> Customer Number: 23460	<input type="checkbox"/> _____, Reg. No. Leydig, Voit & Mayer, Ltd. Two Prudential Plaza, Suite 4900 180 North Stetson Chicago, Illinois 60601-6780 (312) 616-5600 (telephone) (312) 616-5700 (facsimile)
23460 PATENT TRADEMARK OFFICE	
Name	John Kilyk, Jr., Registration No. 30,763
Signature	
Date	September 26, 2001

Certificate of Mailing Under 37 CFR 1.10

I hereby certify that this Utility Patent Application Transmittal and all accompanying documents are being deposited with the United States Postal Service "Express Mail Post Office To Addressee" Service under 37 CFR 1.10 on the date indicated below and is addressed to: Assistant Commissioner of Patents, Box Patent Application, Washington, D.C. 20231.

Peter Phillips	Peter Phillips	September 26, 2001
Name of Person Signing	Signature	Date

Utility (Rev. 11/13/2000)

PATENT  
Attorney Docket No. 213257

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Kovesdi et al.

Art Unit: Not Assigned

Application No. Not Assigned  
(Continuation of U.S. Patent App. No. 08/258,416)

Examiner: Not Assigned

Filed: September 6, 2001

For: COMPLEMENTARY ADENOVIRAL VECTOR  
SYSTEMS AND CELL LINES

**REQUEST FOR DECLARATION OF INTERFERENCE**

Commissioner of Patents  
Washington, D.C. 20231

Dear Sir:

Applicants seek to have an interference declared between this application and a U.S. patent. In support thereof, this Request and the enclosed documents supply information pursuant to 37 C.F.R. §§ 1.607 and 1.608.

**A. 37 C.F.R. § 1.607**

The following information is supplied pursuant to 37 C.F.R. § 1.607(a) and (c):

**(1) Identity of Opposed Patent:**

U.S. Patent 6,127,175 (Vigne et al.).

**(2) Proposed Counts:**

(a) A recombinant cell line for the production of a defective adenovirus, comprising, inserted into its genome, part of an adenovirus E4 region comprising an ORF6 reading frame under the control of a functional promoter, wherein the inserted E4 region does not contain a functional ORF4 reading frame.

(b) A plasmid comprising part of an E4 region of an adenovirus genome carrying a reading frame ORF6 under the control of an inducible promoter.

(c) A defective recombinant adenovirus ΔE1, ΔE4, wherein all or part of the E1 region and the whole of the E4 region is deleted.

(d) A method for the production of a recombinant adenovirus which is defective at least for the E4 region, comprising infecting a cell line comprising, inserted into its genome, part of an adenovirus E4 region comprising an ORF6 reading frame under the control of a functional promoter, wherein the inserted E4 region does not contain a functional ORF4 reading frame, with the E4 defective adenovirus and harvesting the adenovirus.

**(3) and (4) Claims Corresponding to the Proposed Counts:**

The proposed counts correspond exactly to claims 36, 44, 45, and 48 of the present application. All other claims that correspond to one of the proposed counts are dependent on one of these claims. Thus, no other explanation pursuant to Section 1.607(a)(4) is needed.

Proposed Count	U.S. Patent 6,127,175 Claims(s)	Pending Claim(s)
(a)	1, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, and 19	36, 37, 38, 39, 40, 41, 42, and 43
(b)	23, 24, and 25	45, 46, and 47
(c)	20	44
(d)	33	48

**(5) Applying the terms of the pending claims to the disclosure**

The terms of the claims have been applied to the specification in the Preliminary Amendment filed herewith.

**(6) Compliance with 35 U.S.C. § 135(b)**

The claims were added to the application within one year of the issue date of the Vigne '175 patent, as stated in the Preliminary Amendment. As such, the claims are admissible under 35 U.S.C. § 135(b).

**B. Basis of Applicants' Entitlement to Judgment of Priority**

Applicants request judgment based on the respective effective invention dates of the present application and the Vigne '175 patent. The present application is a continuation of U.S. Patent Application 08/258,416, filed June 10, 1994. The Vigne '175 patent claims priority to three French patent applications, the earliest filed of which (serial no. 95 00747), has a January 20, 1995 filing date.


An inventor can derive no benefit from work done abroad before January 1, 1996 with respect to establishing a date of invention in a WTO country (see, e.g., M.P.E.P. § 2138.02; *Kondo v. Martel*, 220 U.S.P.Q. 47 (Bd. Pat. Inter. 1983)). The invention date of the subject matter of the Vigne '175 patent is, as such, limited to the January 20, 1995 filing date of the French '747 priority application. Accordingly, because the effective *filings* date of the present application is June 10, 1994, over six months before the effective *invention* date of the Vigne '175 patent, Applicants are entitled to judgment of priority with respect to the interfering claims.

**C. Conclusion**

Inasmuch as this application claims subject matter interfering with the identified patent and applicants are *prima facie* entitled to a judgment relative to the patentee, the undersigned respectfully urges that an interference between the subject application and the identified patent be declared.

While no fee is believed to be due in connection with this request, the undersigned hereby authorizes the Commissioner of Patents to deduct any fee which might be due to his deposit account, No. 12-1216. A duplicate copy of this Request is enclosed for that purpose.

Respectfully submitted,



John Kilyk Jr., Reg. No. 30763  
One of the Attorneys for Applicants  
**LEYDIG, VOIT & MAYER, LTD.**  
Two Prudential Plaza, Suite 4900  
180 North Stetson  
Chicago, Illinois 60601-6780  
(312) 616-5600 (telephone)  
(312) 616-5700 (facsimile)

Date: September 26, 2001